Total and free methotrexate pharmacokinetics in rheumatoid arthritis patients.
The pharmacokinetics of total and free methotrexate (MTX) were investigated in 50 patients with rheumatoid arthritis. Each patient received 10 mg MTX intramuscularly. The free and total plasma concentrations of MTX were measured over a 36-h period after drug administration by using the Abbott TDx fluorescence polarization immunoassay. Plasma concentrations of MTX were described by a biexponential function. The mean terminal elimination half-lives of total and free MTX were 9.4 and 8.4 h, respectively, and the corresponding mean residence times, 8.5 and 9.2 h. No difference in these parameters was found by comparing total and free MTX. Total plasma clearance of the free fraction averaged 215 ml/min. The statistical comparison of the variations with time of the ratio of free to total MTX during the 36 h after the dose showed that the free fraction was significantly increased for 8 h after drug administration (p < 0.001). To describe these variations, the changes of the free MTX concentrations (unbound) were related to the changes of the total MTX concentrations by using the Hill equation. Mean plasma protein binding ranged from 20 to 57% for these patients.
Edno
L
L
Laboratoire de Pharmacocinétique, CHU Carémeau, Nîmes, France.
Bressolle
F
F
Gomeni
R
R
Bologna
C
C
Sany
J
J
Combe
B
B
D000328:Adult; D000368:Aged; D000704:Analysis of Variance; D018501:Antirheumatic Agents / Q000097:blood / Q000493:pharmacokinetics*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy / Q000378:metabolism*; D005260:Female; D006801:Humans; D008297:Male; D008727:Methotrexate / Q000097:blood / Q000493:pharmacokinetics*; D008875:Middle Aged; D011485:Protein Binding
D018501:Antirheumatic Agents; D008727:Methotrexate